{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:03:15Z","timestamp":1762480995014,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:00:00Z","timestamp":1701043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.gore.2023.101310","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T12:33:34Z","timestamp":1701174814000},"page":"101310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Vulvar cancer management and wrangling recurrent disease: A report from the Society of Gynecologic Oncology journal club"],"prefix":"10.1016","volume":"50","author":[{"given":"Jessica E.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi J.","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian T.","family":"Gien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christa","family":"Nagel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0005","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/IGC.0000000000001195","article-title":"The role of pathological margin distance and prognostic factors after primary surgery in squamous cell carcinoma of the vulva","volume":"28","author":"Arvas","year":"2018","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2023.101310_b0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/gyno.1995.1128","article-title":"Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy","volume":"57","author":"Burke","year":"1995","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101310_b0015","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00428-018-2364-7","article-title":"PD-L1 receptor expression in vulvar carcinomas is HPV-independent","volume":"473","author":"Choschzick","year":"2018","journal-title":"Virchows Arch."},{"issue":"5","key":"10.1016\/j.gore.2023.101310_b0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000259259","article-title":"Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma","volume":"77","author":"Cormio","year":"2009","journal-title":"Oncology."},{"issue":"7","key":"10.1016\/j.gore.2023.101310_b0025","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/0002-9378(79)90119-4","article-title":"An alternate approach to early cancer of the vulva","volume":"133","author":"DiSaia","year":"1979","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0030","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ygyno.2007.02.014","article-title":"Patterns of inguinal groin metastases in squamous cell carcinoma of the vulva","volume":"105","author":"Gonzalez Bosquet","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.gore.2023.101310_b0035","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/IGC.0b013e3181df7423","article-title":"Recurrence rate in vulvar carcinoma in relation to pathological margin distance","volume":"20","author":"Groenen","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.gore.2023.101310_b0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ygyno.2008.07.038","article-title":"Decreased survival in EGFR gene amplified vulvar carcinoma","volume":"111","author":"Growdon","year":"2008","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0045","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0090-8258(90)90064-R","article-title":"Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva","volume":"38","author":"Heaps","year":"1990","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0050","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/gyno.1993.1127","article-title":"Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study)","volume":"49","author":"Homesley","year":"1993","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.gore.2023.101310_b0055","unstructured":"Horowitz NS, Deng W, Monk BJ, Leath CA III, Peterson I, Dizon D, Miller A, Mayadev JS, 2023. A phase II trial evaluating cisplatin and gemcitabine concurrent with intensity-modulated radiation therapy (Imrt) in the treatment of locally advanced squamous cell carcinoma of the vulva: An NRG Oncology Group study. Abstract in Society of Gynecologic Oncology Annual Meeting March 27th, 2023."},{"issue":"1","key":"10.1016\/j.gore.2023.101310_b0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.ygyno.2012.06.028","article-title":"Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva","volume":"127","author":"Horowitz","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101310_b0065","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.gynor.2012.07.002","article-title":"Long term response to erlotinib in a patient with recurrent vulvar carcinoma: Case report and review of literature","volume":"2","author":"Inrhaoun","year":"2012","journal-title":"Gynecol. Oncol. Case Rep."},{"key":"10.1016\/j.gore.2023.101310_b0070","doi-asserted-by":"crossref","unstructured":"Kortekaas KE, Bastiaannet E, van Doorn HC, de Vos van Steenwijk PJ, Ewing-Graham PC, Creutzberg CL, Akdeniz K, Nooij LS, van der Burg SH, Bosse T, van Poelgeest MIE, 2020. Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes. Gynecol Oncol. 159(3):649-656. doi: 10.1016\/j.ygyno.2020.09.024.","DOI":"10.1016\/j.ygyno.2020.09.024"},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0075","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/AOG.0b013e3181b12f99","article-title":"Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial","volume":"114","author":"Kunos","year":"2009","journal-title":"Obstet. Gynecol."},{"issue":"31","key":"10.1016\/j.gore.2023.101310_b0080","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.2011.41.2528","article-title":"Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study","volume":"30","author":"Levenback","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0085","doi-asserted-by":"crossref","first-page":"dju426","DOI":"10.1093\/jnci\/dju426","article-title":"AGO-CaRE 1 investigators. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study","volume":"107","author":"Mahner","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0090","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ygyno.2011.11.003","article-title":"A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study","volume":"124","author":"Moore","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"31","key":"10.1016\/j.gore.2023.101310_b0095","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the Phase I\/II CheckMate 358 Trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0100","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2007.05.006","article-title":"Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva","volume":"106","author":"Olawaiye","year":"2007","journal-title":"Gynecol. Oncol."},{"issue":"32","key":"10.1016\/j.gore.2023.101310_b0105","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.21.00006","article-title":"Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II","volume":"39","author":"Oonk","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.gore.2023.101310_b0110","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.ejso.2018.05.031","article-title":"Surgical margins in squamous cell carcinoma, different for the vulva?","volume":"44","author":"Pleunis","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.gore.2023.101310_b0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ygyno.2022.01.029","article-title":"Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study","volume":"166","author":"Shapira-Frommer","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0120","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.AOG.0000202404.55215.72","article-title":"Carcinoma of the vulva","volume":"107","author":"Stehman","year":"2006","journal-title":"Obstet Gynecol."},{"issue":"1","key":"10.1016\/j.gore.2023.101310_b0125","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2015.09.077","article-title":"Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I","volume":"140","author":"Te Grootenhuis","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/0090-8258(86)90138-1","article-title":"Phase II trials of cisplatin and piperazinedione in advanced or recurrent squamous cell carcinoma of the vulva: a Gynecologic Oncology Group Study","volume":"23","author":"Thigpen","year":"1986","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.gore.2023.101310_b0135","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2007.14.0566","article-title":"Sentinel node dissection is safe in the treatment of early-stage vulvar cancer","volume":"26","author":"Van der Zee","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.gore.2023.101310_b0140","first-page":"187","article-title":"The anatomy of the lymphatic drainage of the vulva and its influence on the radical operation for carcinoma","volume":"3","author":"Way","year":"1948","journal-title":"Ann R Coll Surg Engl."},{"issue":"9","key":"10.1016\/j.gore.2023.101310_b0145","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/annonc\/mdp043","article-title":"Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group)","volume":"20","author":"Witteveen","year":"2009","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.gore.2023.101310_b0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejca.2016.09.038","article-title":"Role of tumour-free margin distance for loco-regional control in vulvar cancer-a subset analysis of the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie CaRE-1 multicenter study","volume":"69","author":"Woelber","year":"2016","journal-title":"Eur J Cancer."},{"issue":"6","key":"10.1016\/j.gore.2023.101310_b0155","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3727\/096504020X16076861118243","article-title":"Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature","volume":"28","author":"Woelber","year":"2021","journal-title":"Oncol Res."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0160","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ygyno.2020.06.503","article-title":"Tumor-free margins and local recurrence in squamous cell carcinoma of the vulva","volume":"158","author":"Yang","year":"2020","journal-title":"Gynecol Oncol."},{"issue":"3","key":"10.1016\/j.gore.2023.101310_b0165","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.ygyno.2021.03.013","article-title":"Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study","volume":"161","author":"Zach","year":"2021","journal-title":"Gynecol Oncol."}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923003272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:58:42Z","timestamp":1762480722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923003272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":33,"alternative-id":["S2352578923003272"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101310","relation":{},"ISSN":["2352-5789"],"issn-type":[{"type":"print","value":"2352-5789"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vulvar cancer management and wrangling recurrent disease: A report from the Society of Gynecologic Oncology journal club","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101310"}}